Table 3 MRI metrics at baseline and follow-up.

From: Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration

  

PPMS

PPMS

PPMS-NP

PPMS-P

 

Baseline

1-Y FU

p-valuea

Baseline

1-Y FU

p-valuea

Baseline

1-Y FU

p-valuea

T1 lesion

3.31

(± 5.41)

3.92

(± 6.61)

0.005

3.51

(± 6.68

4.49

(± 8.55)

0.015

3.08

(± 3.93)

3.27

(± 3.91)

0.139

T2 lesion

5.71

(± 7.79)

6.43

(± 8.55)

0.087

5.89

(± 9.62)

6.75

(± 10.15)

0.139

5.50

(± 5.68)

6.06

(± 6.94)

0.314

CblV

114.63

(± 13.16)

112.02

(± 12.62)

 < 0.001

110.33

(± 14.57)

108.67

(± 14.77)

0.005

119.40

(± 10.12)

115.74

(± 9.15)

0.008

CblGMV

86.85

(± 9.33)

85.07

(± 8.62)

 < 0.001

83.42

(± 9.35)

82.54

(± 9.29)

0.013

90.67

(± 8.13)

87.88

(± 7.28)

0.008

CblWMV

27.77

(± 5.48)

26.95

(± 5.36)

 < 0.001

26.91

(± 6.66)

26.14

(± 6.56)

0.017

28.72

(± 3.98)

27.85

(± 3.80)

0.008

  1. Statistically significant differences between groups (p < 0.05) are highlighted in bold.
  2. aWilcoxon signed rank test.
  3. 1-Y FU = 1-year follow-up; CblV, cerebellar volume; CblGMV, cerebellar grey matter volume; CblWMV, cerebellar white matter volume. All values are expressed in mL. Values represent mean (± SD).
Back to article page